Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Folylpolyglutamate synthase is an ATP-dependent enzyme responsible for the addition of multiple glutamate residues to the gamma-carboxy group of folate and its derivatives, a process known as polyglutamylation. This modification is essential for retaining active forms of folates within cellular compartments—particularly in proliferating cells—and supports critical metabolic processes like one-carbon transfer reactions required for nucleotide biosynthesis. The enzyme plays a central role in both cytosolic and mitochondrial pools of polyglutamated folates, impacting cell survival and growth. In cancer therapy, the activity level of FPGS influences the effectiveness of antifolate drugs because these agents must be polyglutamated to remain active inside target cells. Defects or altered expression in this enzyme can disrupt normal cell function or reduce drug efficacy.
Drugs such as antifolates act as competitive inhibitors by mimicking tetrahydrofolate structure; their effectiveness depends on polyglutamylation by FPGS to increase retention and potency inside cells
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Folylpolyglutamate synthase (FPGS).